相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。REGULATION AND METABOLIC FUNCTIONS OF mTORC1 AND mTORC2
Angelia Szwed et al.
PHYSIOLOGICAL REVIEWS (2021)
Small-molecule inhibition of Lats kinases may promote Yap-dependent proliferation in postmitotic mammalian tissues
Nathaniel Kastan et al.
NATURE COMMUNICATIONS (2021)
Decellularized Cell Culture ECMs Act as Cell Differentiation Inducers
Mahmut Parmaksiz et al.
STEM CELL REVIEWS AND REPORTS (2020)
Differential effects of integrin-linked kinase inhibitor Cpd22 on severe pulmonary hypertension in male and female rats
Yuanjun Shen et al.
PULMONARY CIRCULATION (2020)
PATIENTS WITH SEVERE PULMONARY ARTERIAL HYPERTENSION TREATED WITH ABI-009, NAB-SIROLIMUS, AN MTOR INHIBITOR: INTERIM RESULTS FROM A PHASE 1 CLINICAL TRIAL
Marc Simon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension
Astrid Weiss et al.
NATURE COMMUNICATIONS (2019)
The Hippo Signaling Pathway in Development and Disease
Yonggang Zheng et al.
DEVELOPMENTAL CELL (2019)
Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension
Thenappan Thenappan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2018)
Pulmonary Arterial Stiffness: An Early and Pervasive Driver of Pulmonary Arterial Hypertension
Wei Sun et al.
FRONTIERS IN MEDICINE (2018)
Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats
Andressa Pena et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2017)
Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2
Paul B. Dieffenbach et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2017)
From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics Targeting Cell Growth and Proliferation Signaling Hubs
Soni Savai Pullamsettit et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension
Tatiana V. Kudryashova et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension
Amal Houssaini et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2016)
TSC2 N-terminal lysine acetylation status affects to its stability modulating mTORC1 signaling and autophagy
Ana Garcia-Aguilar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension
Thomas Bertero et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds
Michael S. Bonkowski et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Sphingosine-1-phosphate is involved in the occlusive arteriopathy of pulmonary arterial hypertension
Salina Gairhe et al.
PULMONARY CIRCULATION (2016)
Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus
Sowmya Venkatasubramanian et al.
OPEN HEART (2016)
Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension
Fei Liu et al.
JCI INSIGHT (2016)
Deficiency of Akt1, but not Akt2, attenuates the development of pulmonary hypertension
Haiyang Tang et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2015)
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Hung Huynh et al.
MOLECULAR CANCER THERAPEUTICS (2015)
A YAP/TAZ-miR-130/301 molecular circuit exerts systems-level control of fibrosis in a network of human diseases and physiologic conditions
Thomas Bertero et al.
SCIENTIFIC REPORTS (2015)
Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit
Thomas Bertero et al.
CELL REPORTS (2015)
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
James G. Krueger et al.
PLoS One (2015)
A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes
Arun Baksi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity
Eric E. Kelley et al.
CARDIOVASCULAR RESEARCH (2014)
Pulmonary Hypertension Surveillance United States, 2001 to 2010
Mary G. George et al.
CHEST (2014)
Mammalian Target of Rapamycin Complex 2 ( mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension
Dmitry A. Goncharov et al.
CIRCULATION (2014)
Role for DNA Damage Signaling in Pulmonary Arterial Hypertension
Jolyane Meloche et al.
CIRCULATION (2014)
MicroRNA-124 Controls the Proliferative, Migratory, and Inflammatory Phenotype of Pulmonary Vascular Fibroblasts
Daren Wang et al.
CIRCULATION RESEARCH (2014)
Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
Ning Liang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension
Rajkumar Savai et al.
NATURE MEDICINE (2014)
Rapamycin Reverses Pulmonary Artery Smooth Muscle Cell Proliferation in Pulmonary Hypertension
Amal Houssaini et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2013)
Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man
Ethan Hoffmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Xiaobei Zhang et al.
CURRENT CANCER DRUG TARGETS (2013)
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension
Nicholas W. Morrell et al.
PULMONARY CIRCULATION (2013)
Pathogenesis of pulmonary arterial hypertension: lessons from cancer
Christophe Guignabert et al.
EUROPEAN RESPIRATORY REVIEW (2013)
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients
Vincent Cottin et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States How REVEAL Differs From Historic and Non-US Contemporary Registries
Adaani E. Frost et al.
CHEST (2011)
mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia
Vera P. Krymskaya et al.
FASEB JOURNAL (2011)
Tuberous sclerosis complex: linking cancer to metabolism
Virginie Mieulet et al.
TRENDS IN MOLECULAR MEDICINE (2010)
PI3K/mTORC1 activation in hamartoma syndromes Therapeutic prospects
Vera P. Krymskaya et al.
CELL CYCLE (2009)
Resveratrol Prevents Monocrotaline-Induced Pulmonary Hypertension in Rats
Anna Csiszar et al.
HYPERTENSION (2009)
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
Nicholas W. Morrell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford et al.
NATURE REVIEWS CANCER (2009)
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth
Jingxiang Huang et al.
BIOCHEMICAL JOURNAL (2008)
The relationship between the components of pulmonary artery pressure remains constant under all conditions in both health and disease
Raheel Syyed et al.
CHEST (2008)
Pulmonary lymphangioleiomyomatosis (LAM): Progress and current challenges
Elena A. Goncharova et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases
Mitchell D. Knutson et al.
NUTRITION REVIEWS (2008)
Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension
Fares A. Masri et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2007)
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats
Masahiko Oka et al.
CIRCULATION RESEARCH (2007)
TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase
H Chong-Kopera et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Assays for in vitro monitoring of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cell migration
Elena A. Goncharova et al.
NATURE PROTOCOLS (2006)
Metabolic activation of AMP kinase in vascular smooth muscle
LJ Rubin et al.
JOURNAL OF APPLIED PHYSIOLOGY (2005)
TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase
E Goncharova et al.
JOURNAL OF CELL BIOLOGY (2004)
AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation
D Nagata et al.
CIRCULATION (2004)
Cellular and molecular pathobiology of pulmonary arterial hypertension
M Humbert et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-β and ERK-1/2
GA Finlay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis
S Basu et al.
MOLECULAR CELL (2003)
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation -: A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM)
EA Goncharova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cre/LoxP-mediated inactivation of the murine Pten tumor suppressor gene
R Lesche et al.
GENESIS (2002)
Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension
L Taraseviciene-Stewart et al.
FASEB JOURNAL (2001)
分享论文
